Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference44 articles.
1. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333(19):1253–8. https://doi.org/10.1056/NEJM199511093331904.
2. Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(18):2804–11. https://doi.org/10.1182/blood-2014-02-522128.
3. US Food and Drug Administration. Soliris: full prescribing information; 2007. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125166s422lbl.pdf. Accessed Jun 2019.
4. Höchsmann B, Lee JW, Kulagin A, Hillmen P, Wilson A, et al. Effect of eculizumab in paroxysmal nocturnal hemoglobinuria (PNH) patients with or without high disease activity: results from the International PNH Registry. EHA Learning Center. 207;181785.
5. Hillmen P, Muus P, Roth A, Elebute MO, Risitano AM, Schrezenmeier H, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162(1):62–73. https://doi.org/10.1111/bjh.12347.
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献